文献速递淋巴瘤

奥法木单抗对比利妥昔单抗挽救性化学免疫治疗复发或难治性弥漫大B细胞淋巴瘤:ORCHARRD研究

Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study.
PubMed 文献 · J Clin Oncol · 2016-12-28

ORCHARRD研究将447例首次复发或对一线R-CHOP样方案难治的CD20+弥漫大B细胞淋巴瘤患者随机分配接受R-DHAP或O-DHAP三周期挽救治疗,后续行自体干细胞移植。O-DHAP与R-DHAP在2年无进展生存率(24% vs 26%,HR 1.12,95%CI 0.89-1.42,P=0.33)、无事件生存率和总生存率上均无显著差异,两组疗效无差别。

要点

  • O-DHAP与R-DHAP在复发/难治DLBCL挽救治疗中疗效无显著差异。
  • 2年PFS:O-DHAP组24% vs R-DHAP组26%(HR 1.12,95%CI 0.89-1.42,P=0.33)。
  • ASCT前PET阴性对更优结局具有高度预测作用。

核心结论

  • O-DHAP与R-DHAP作为复发或难治性弥漫大B细胞淋巴瘤的挽救治疗,疗效无差异。

研究设计与样本

  • 随机对照研究,纳入447例年龄≥18岁、CD20+弥漫大B细胞淋巴瘤、首次复发或对一线R-CHOP样方案难治的患者,随机分配接受三周期R-DHAP或O-DHAP。
  • O 1,000 mg或R 375 mg/m2共输注4次(第1周期第1天和第8天;第2和第3周期第1天)。
  • 两周期后有反应者接受第三周期,随后行大剂量治疗和自体干细胞移植。
  • 主要终点为无进展生存期,两周期后未达缓解计为事件。

主要发现

  • 2010年3月至2013年12月共随机分配447例;中位年龄57岁(范围18-83岁);17%年龄≥65岁;63%为III和IV期;71%未达完全缓解或一线R-CHOP后缓解持续<1年。
  • O-DHAP组缓解率38%(完全缓解15%)vs R-DHAP组42%(完全缓解22%)。
  • 按方案完成自体干细胞移植:O组74例(33%)vs R组83例(37%)。
  • 2年无进展生存率:O-DHAP组24% vs R-DHAP组26%(HR 1.12;95%CI 0.89-1.42;P=0.33)。
  • 2年无事件生存率:O-DHAP组16% vs R-DHAP组18%(HR 1.10;P=0.35);2年总生存率:O-DHAP组41% vs R-DHAP组38%(HR 0.90;P=0.38)。

关键数值与推荐

  • O 1,000 mg或R 375 mg/m2,共4次输注(第1周期第1天和第8天;第2和第3周期第1天)。

临床怎么用

  • O-DHAP与R-DHAP均可作为复发或难治性弥漫大B细胞淋巴瘤的挽救治疗方案(原文结论为两者疗效无差异)。
  • 自体干细胞移植前PET阴性对更优结局具有高度预测作用。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose We compared the efficacy of ofatumumab (O) versus rituximab (R) in combination with cisplatin, cytarabine, and dexamethasone (DHAP) salvage treatment, followed by autologous stem-cell transplantation (ASCT) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Patients and Methods Patients with CD20+ DLBCL age ≥ 18 years who had experienced their first relapse or who were refractory to first-line R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)-like treatment were randomly assigned between three cycles of R-DHAP or O-DHAP. Either O 1,000 mg or R 375 mg/m2 was administered for a total of four infusions (days 1 and 8 of cycle 1; day 1 of cycles 2 and 3 of DHAP). Patients who experienced a response after two cycles of treatment received the third cycle, followed by high-dose therapy and ASCT. Primary end point was progression-free survival (PFS), with failure to achieve a response after cycle 2 included as an event. Results Between March 2010 and December 2013, 447 patients were randomly assigned. Median age was 57 years (range, 18 to 83 years); 17% were age ≥ 65 years; 63% had stage III and IV disease; 71% did not achieve complete response (CR) or experience response for < 1 year on first-line R-CHOP. Response rate for O-DHAP was 38% (CR, 15%) versus 42% (CR, 22%) for R-DHAP. ASCT on protocol was completed by 74 patients (33%) in the O arm and 83 patients (37%) in the R arm. PFS, event-free survival, and overall survival were not significantly different between O-DHAP versus R-DHAP: PFS at 2 years was 24% versus 26% (hazard ratio [HR], 1.12; 95% CI, 0.89 to 1.42; P = .33); event-free survival at 2 years was 16% versus 18% (HR, 1.10; P = .35); and overall survival at 2 years was 41% versus 38% (HR, 0.90; P = .38). Positron emission tomography negativity before ASCT was highly predictive for superior outcome. Conclusion No difference in efficacy was found between O-DHAP and R-DHAP as salvage treatment of relapsed or refractory DLBCL.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. van Imhoff GW, McMillan A, Matasar MJ, et al. Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. J Clin Oncol. 2016. PMID: 28029326. doi:10.1200/JCO.2016.69.0198

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。